Last reviewed · How we verify

Bicillin C-R — Competitive Intelligence Brief

Bicillin C-R (benzathine benzylpenicillin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: benzathine benzylpenicillin. Area: Metabolic.

marketed benzathine benzylpenicillin Metabolic Live · refreshed every 30 min

Target snapshot

Bicillin C-R (benzathine benzylpenicillin) — Pfizer. Bicillin C-R works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bicillin C-R TARGET benzathine benzylpenicillin Pfizer marketed benzathine benzylpenicillin 1952-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (benzathine benzylpenicillin class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bicillin C-R — Competitive Intelligence Brief. https://druglandscape.com/ci/benzathine-benzylpenicillin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: